search
Back to results

QuickVue Influenza A+B Clinical Field Trial

Primary Purpose

Influenza

Status
Completed
Phase
Not Applicable
Locations
Australia
Study Type
Interventional
Intervention
Swab Specimen Collection (QuickVue)
Sponsored by
Quidel Corporation
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Influenza

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Subjects must have:

  • Fever (>38°C) (at time of visit or within the previous 48 hrs by history) and at least two of the following symptoms:

    • Chills/sweats
    • Cough
    • Dyspnea (labored, difficult breathing)
    • Fatigue
    • Headache
    • Myalgia (deep muscle aches)
    • Nasal congestion
    • Runny nose
    • Sore throat

Exclusion Criteria:

  • Patients who are undergoing treatment with antivirals, now or within the last 7 days cannot be included in this study.

Sites / Locations

  • Sydney Airport Medical Centre

Outcomes

Primary Outcome Measures

Sensitivity and Specificity

Secondary Outcome Measures

Sensitivity and Specificity

Full Information

First Posted
June 22, 2007
Last Updated
January 23, 2008
Sponsor
Quidel Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT00491283
Brief Title
QuickVue Influenza A+B Clinical Field Trial
Official Title
Comparison of Swab Types for Specimen Collection
Study Type
Interventional

2. Study Status

Record Verification Date
January 2008
Overall Recruitment Status
Completed
Study Start Date
July 2006 (undefined)
Primary Completion Date
August 2006 (Actual)
Study Completion Date
August 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Quidel Corporation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A comparative study of different swab types used for collection of specimens for rapid inluenza testing

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Single
Allocation
Randomized

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Swab Specimen Collection (QuickVue)
Primary Outcome Measure Information:
Title
Sensitivity and Specificity
Time Frame
five months
Secondary Outcome Measure Information:
Title
Sensitivity and Specificity
Time Frame
Positive and Negative Predictive Values

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects must have: Fever (>38°C) (at time of visit or within the previous 48 hrs by history) and at least two of the following symptoms: Chills/sweats Cough Dyspnea (labored, difficult breathing) Fatigue Headache Myalgia (deep muscle aches) Nasal congestion Runny nose Sore throat Exclusion Criteria: Patients who are undergoing treatment with antivirals, now or within the last 7 days cannot be included in this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Keller, MD
Organizational Affiliation
Sydney Airport medical Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sydney Airport Medical Centre
City
Mascot
State/Province
New South Wales
ZIP/Postal Code
2020
Country
Australia

12. IPD Sharing Statement

Learn more about this trial

QuickVue Influenza A+B Clinical Field Trial

We'll reach out to this number within 24 hrs